ER+/HER2-BREAST CANCER Clinical Trials

17 clinical trials for ER+/HER2-BREAST CANCER across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer — RECRUITING · PHASE2
• A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF PALAZESTRANT WITH RIBOCICLIB VERSUS LETROZOLE WITH RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF ER+, HER2–ADVANCED BREAST CANCER (OPERA-02) — RECRUITING · PHASE3
• CAPECITABINE FOR TARGETED ERADICATION OF ARISING CTDNA MOLECULAR RESIDUAL DISEASE IN ER+/HER2- NEGATIVE BREAST CANCER — RECRUITING
• A PHASE I/II, OPEN-LABEL, MULTI-CENTER TRIAL OF [177LU]LU-NEOB IN COMBINATION WITH CAPECITABINE IN ADULT PATIENTS WITH GRPR+, ER+, HER2- METASTATIC BREAST CANCER AFTER PROGRESSION ON PREVIOUS ENDOCRINE THERAPY IN COMBINATION WITH A CDK4/6 INHIBITOR. — RECRUITING · PHASE1
• A LIQUID-BIOPSY INFORMED PLATFORM TRIAL TO EVALUATE TREATMENT IN CDK4/6-INHIBITOR RESISTANT ER+/HER2- METASTATIC BREAST CANCER — RECRUITING
• A PHASE III RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER — RECRUITING · PHASE3
• AN OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY EVALUATING THE ACTIVITY OF LASOFOXIFENE RELATIVE TO FULVESTRANT FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION — RECRUITING
• SPatial Heterogeneity of INtratumoral drug distribution — NOT_YET_RECRUITING · PHASE4
• A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756) — TERMINATED · PHASE3
• SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer — NOT_YET_RECRUITING · PHASE2
• A Study to Learn How a Tablet Compared with an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up into the Blood in Healthy Adults. — OTHER · PHASE1
• A Study to Learn how Various Tablets of the Study Medicine Called Vepdegestrant are Taken up into the Blood in Healthy Adults — OTHER · PHASE1
• A RANDOMIZED PHASE II WINDOW OF OPPORTUNITY CLINICAL TRIAL OF PD-1 +/- IL-4 INHIBITION EARLY STAGE ER+HER2- BREAST CANCER — NOT_YET_RECRUITING · PHASE2
• A RANDOMIZED PHASE 2 NON-INFERIORITY TRIAL OF (Z)-ENDOXIFEN AND EXEMESTANE + GOSERELIN AS NEOADJUVANT TREATMENT FOR PREMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER — NOT_YET_RECRUITING · PHASE2
• A PHASE 1B TRIAL OF ARV-471 IN COMBINATION WITH EVEROLIMUS IN PATIENTS WITH ER+, HER2- ADVANCED OR METASTATIC BREAST CANCER — NOT_YET_RECRUITING · PHASE1
• RANDOMIZED, NON-COMPARATIVE NEOADJUVANT PHASE II STUDY IN PATIENTS WITH ER+ / HER2- BREAST CANCER ¿ 2 CM WITH SAFETY RUN-IN, ASSISSING NIVOLUMAB + ABEMACICLIB OR PALBOCICLIB + ANASTROZOLE — COMPLETED · PHASE2

Refine this search